Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Solid Tumors 1 Recurrence 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Lymphoma 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Advanced Cancers 1

Interventions

Trastuzumab 243 Paclitaxel 193 Cyclophosphamide 158 Docetaxel 134 Letrozole 113 Capecitabine 113 Fulvestrant 106 Doxorubicin 103 Bevacizumab 87 Carboplatin 81 exemestane 80 Anastrozole 79 Lapatinib 70 Tamoxifen 69 Albumin-Bound Paclitaxel 57 palbociclib 54 pertuzumab 53 Taxes 51 Gemcitabine 50 Radiotherapy 46 eribulin 43 pembrolizumab 41 Everolimus 41 Ado-Trastuzumab Emtansine 41 Vinorelbine 38 130-nm albumin-bound paclitaxel 35 ixabepilone 32 Epirubicin 28 pegfilgrastim 25 liposomal doxorubicin 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Breast Neoplasms × ridaforolimus × Clear all

NCT01605396 2019-03-25

MK-8669-064

Merck Sharp & Dohme LLC

Phase 2 Completed

80 enrolled 13 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡